Morepen Laboratories

Morepen Laboratories EBIT

The EBIT of Morepen Laboratories (MOREPENLAB.NS) as of Oct 24, 2026 is 1.45 B INR. In the previous year, EBIT was 1.25 B INR — a change of 15.93% (higher).

EBIT

1.45 BINR

YoY

15.93%

Last updated:

In 2025, Morepen Laboratories's EBIT was 1.45 B INR, a 15.93% increase from the 1.25 B INR EBIT recorded in the previous year.

The Morepen Laboratories EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2018
304.06 M INR
Jan 1, 2019
276.15 M INR
Jan 1, 2020
316.09 M INR
Jan 1, 2021
882.31 M INR
Jan 1, 2022
1.09 B INR
Jan 1, 2023
516.03 M INR
Jan 1, 2024
1.25 B INR
Jan 1, 2025
1.45 B INR
The Morepen Laboratories EBIT history
YEAREBITYoY
1.45 BINR+15.93%
1.25 BINR+142.54%
516.03 MINR-52.67%
1.09 BINR+23.57%
882.31 MINR+179.14%
316.09 MINR+14.46%
276.15 MINR-9.18%
304.06 MINR+10.66%
274.75 MINR+25.08%
219.67 MINR+112.09%
103.57 MINR+220.66%
32.30 MINR-121.68%
-149.00 MINR-48.26%
-288.00 MINR-32.08%
-424.00 MINR+15.22%
-368.00 MINR-24.44%
-487.00 MINR-16.03%
-580.00 MINR+42.16%
-408.00 MINR-5.34%
-431.00 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Morepen Laboratories Revenue

Morepen Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
6.07 B INR
304.06 M INR
295.91 M INR
Jan 1, 2019
7.69 B INR
276.15 M INR
288.49 M INR
Jan 1, 2020
8.53 B INR
316.09 M INR
335.79 M INR
Jan 1, 2021
11.88 B INR
882.31 M INR
970.86 M INR
Jan 1, 2022
15.47 B INR
1.09 B INR
1.02 B INR
Jan 1, 2023
14.18 B INR
516.03 M INR
386.75 M INR
Jan 1, 2024
16.90 B INR
1.25 B INR
961.60 M INR
Jan 1, 2025
18.12 B INR
1.45 B INR
1.18 B INR

Morepen Laboratories Margins

Morepen Laboratories stock margins

The Morepen Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Morepen Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Morepen Laboratories.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
39.05 %
5.01 %
4.88 %
Jan 1, 2019
35.09 %
3.59 %
3.75 %
Jan 1, 2020
34.13 %
3.71 %
3.94 %
Jan 1, 2021
33.78 %
7.43 %
8.17 %
Jan 1, 2022
31.41 %
7.05 %
6.57 %
Jan 1, 2023
29.87 %
3.64 %
2.73 %
Jan 1, 2024
33.89 %
7.40 %
5.69 %
Jan 1, 2025
32.31 %
8.01 %
6.51 %

Morepen Laboratories Stock analysis

What does Morepen Laboratories do? Morepen Laboratories Ltd. generates revenue through the manufacturing and marketing of bulk drugs, pharmaceutical formulations, and home health products. The company produces active pharmaceutical ingredients (APIs) such as Apixaban, Edoxaban, Sitagliptin, and Rivaroxaban, which are sold to other pharmaceutical manufacturers. Its finished formulations, including Intebact Capsules, Intelicaps Lax, and Rythmix Kid Syrup, are marketed under its own brand for direct consumer sales. Home health products like the Dr. Morepen 49W Room Air Purifier and Dr. Morepen VP06 Breathe Free Vaporizer are sold directly to consumers through retail channels. The company's subsidiaries, Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited, support these product lines by handling specific manufacturing and distribution tasks. The primary customers for APIs are pharmaceutical companies seeking bulk ingredients for their own formulations. Finished formulations target healthcare consumers and pharmacies, while home health products are sold to households and medical facilities. The company's product segments are clearly divided: APIs for industrial clients, branded formulations for retail consumers, and home health devices for personal use. This segmentation allows Morepen to serve multiple market segments without overlapping product lines. Morepen's revenue streams are diversified across three main areas: API sales to pharmaceutical manufacturers, direct-to-consumer sales of branded formulations, and retail sales of home health products. The company's subsidiaries play a key role in supporting each segment, with Dr. Morepen Limited handling branded formulations, Morepen Devices Limited managing home health devices, and Total Care Limited likely supporting broader healthcare services. This structure ensures that each product line is efficiently managed and marketed to its respective target audience. Morepen Laboratories is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Morepen Laboratories's EBIT

Morepen Laboratories's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Morepen Laboratories's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Morepen Laboratories's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Morepen Laboratories’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Morepen Laboratories stock

EBIT of Morepen Laboratories is 1.45 B INR in 2025.

EBIT of Morepen Laboratories changed from 1.25 B INR to 1.45 B INR, representing a 15.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Morepen Laboratories since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Morepen Laboratories historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Morepen Laboratories

All Key Metrics — Morepen Laboratories